Immune checkpoint inhibitors, including monoclonal antibodies against programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1), either as monotherapy or combination therapy, have made a breakthrough in clinical treatment for patients with advanced NSCLC (86). Here, CD274 is linked to non-small cell lung carcinoma.